Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy
Atwell LL, Zhang Z, Mori M, Farris P, Vetto JT, Naik AM, Oh KY, Thuillier P, Ho E, Shannon J
Cancer prevention research (Philadelphia, Pa.) · 100 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
- Consumo medido con
- Biomarcadores de consumo
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Cancer Institute
- Gobierno
- National Institute of Environmental Health Sciences
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NCI NIH HHS
- Gobierno
- NIEHS NIH HHS
- Gobierno
- NCATS NIH HHS
- Subvenciones
- National Cancer Institute (P30 CA-069533); National Institute of Environmental Health Sciences (P30ES000210); National Center for Advancing Translational Sciences (UL1TR000128); National Cancer Institute (R21 CA132236-01A2); National Cancer Institute (P01 CA090890); National Cancer Institute (R21 CA132236)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2015-10-28 · Cancer Prev Res (Phila) · vol. 8 · número 12 · págs. 1184–1191
- Editorial
- American Association for Cancer Research
- Citado
- 125 citas · más que el 92% de estudios similares · 3.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 55 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Histone Deacetylase Inhibitors Research · Family Support in Illness
- Palabras clave
- Sulforaphane, Medicine, Breast cancer, Ductal carcinoma, Internal medicine, Oncology, Glucoraphanin, Biopsy, Cancer, Cancer research, Biology
- MeSH
- humans, carcinoma, intraductal, noninfiltrating, breast neoplasms, isothiocyanates, sulfoxides, anticarcinogenic agents, chemoprevention, immunohistochemistry, double-blind method, biological availability, dietary supplements, female, mass spectrometry, biomarkers, tumor
10 autores
- Lauren L. Atwell🇺🇸Oregon State University; California State University, Chico
- Zhenzhen Zhang🇺🇸Oregon Health & Science University
- Motomi Mori🇺🇸Oregon Health & Science University
- Paige E. Farris🇺🇸Oregon Health & Science University
- John T. Vetto🇺🇸Oregon Health & Science University
- Arpana M. Naik🇺🇸Oregon Health & Science University
- Karen Y. Oh🇺🇸Oregon Health & Science University
- Philippe Thuillier🇺🇸Oregon Health & Science University
- Emily H. Ho🇺🇸Oregon State University; Oregon University System
- Jackilen Shannon🇺🇸 · autor de correspondenciaOregon Health & Science University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Epidemiologic studies suggest a protective effect of cruciferous vegetables on breast cancer. Sulforaphane (SFN), an active food component derived from crucifers, has been shown to be effective in breast cancer chemoprevention. This study evaluated the chemopreventive effect of SFN on selective biomarkers from blood and breast tissues. In a 2- to 8-week double-blinded, randomized controlled trial, 54 women with abnormal mammograms and scheduled for breast biopsy were randomized to consume a placebo or a glucoraphanin (GFN) supplement providing SFN (n = 27). Plasma and urinary SFN metabolites, peripheral blood mononuclear cell (PBMC) histone deacetylase (HDAC) activity, and tissue biomarkers (H3K18ac, H3K9ac, HDAC3, HDAC6, Ki-67, p21) were measured before and after the intervention in benign, ductal carcinoma in situ, or invasive ductal carcinoma breast tissues. Within the supplement group, Ki-67 (P = 0.003) and HDAC3 (P = 0.044) levels significantly decreased in benign tissue. Pre-to-postintervention changes in these biomarkers were not significantly different between treatment groups after multiple comparison adjustment. GFN supplementation was associated with a significant decrease in PBMC HDAC activity (P = 0.04). No significant associations were observed between SFN and examined tissue biomarkers when comparing treatment groups. This study provides evidence that GFN supplementation for a few weeks is safe but may not be sufficient for producing changes in breast tissue tumor biomarkers. Future studies employing larger sample sizes should evaluate alternative dosing and duration regimens to inform dietary SFN strategies in breast cancer chemoprevention.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.